BBIO vs NVST
BridgeBio Pharma, Inc. vs Envista Holdings — AI-powered side-by-side comparison
BBIO
BridgeBio Pharma, Inc.
65
Insufficient Data
VS
NVST
Envista Holdings
76
Strong Buy
| Metric | BBIO | NVST |
|---|
| AI Score |
65
|
76
|
| Price |
$83.71
|
$28.51
|
| P/E Ratio |
-23.38×
|
48.34×
|
| ROE |
35.1%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
93.1%
|
55.5%
|
| Debt / Equity |
-0.99×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.9
|
59.3
|
| Beta |
0.983
|
0.861
|
| Expected Upside |
—
|
+1.4%
|
AI Committee View
Current Innellis committee reasoning for BBIO versus NVST.
NVST leads by 11 points.
NVST scores 76/100 (Strong Buy) versus BBIO at 65/100 (Insufficient Data).
BBIO Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.